nach oben

Die Innere Medizin

Erschienen in:

08.08.2019 | Typ-1-Diabetes | Schwerpunkt: Neue Diabetestherapien

Insulintherapie – neue Insulinanaloga

verfasst von: Dr. med. M. Ehren, Prof. Dr. med. H. H. Klein

Erschienen in: Die Innere Medizin | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Insulintherapie des Diabetes mellitus steht mittlerweile eine Fülle von schnell und lang wirkenden Insulinanaloga zur Verfügung, die die physiologische Insulinsekretion besser nachahmen als Normalinsuline. Durch den Einsatz von ultraschnellem Mahlzeiteninsulin können postprandiale Glukoseanstiege reduziert werden. Neuere lang wirkende Insulinanaloga zeigen einen sehr gleichmäßigen Wirkverlauf und reduzieren im Vergleich zu Insulinanaloga der ersten Generation noch einmal die Hypoglykämiegefahr, insbesondere in Bezug auf nächtliche Hypoglykämien. Zukünftige Entwicklungen fokussieren sich auf eine weitere Beschleunigung der Mahlzeiteninsulinwirkung bei gleichzeitig kürzerer Wirkdauer und auf eine noch längere Wirkung von lang wirkenden Insulinanaloga.

Andersen G, Meiffren G, Lamers D et al (2018) Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab 20:2627–2632CrossRef

Becker RH, Dahmen R, Bergmann K et al (2015) New insulin glargine 300 Units . mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units . mL-1. Diabetes Care 38:637–643PubMed

Bergenstal RM, Bailey TS, Rodbard D et al (2017) Comparison of insulin Glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 40:554–560CrossRef

Bergenstal RM, Lunt H, Franek E et al (2016) Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab 18:1081–1088CrossRef

Blevins TC, Dahl D, Rosenstock J et al (2015) Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus(R)) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab 17:726–733CrossRef

Bode BW, Buse JB, Fisher M et al (2013) Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2‑year results of a randomized clinical trial. Diabet Med 30:1293–1297CrossRef

Bolli GB, Riddle MC, Bergenstal RM et al (2017) Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes Metab 43:351–358CrossRef

Cahn A, Miccoli R, Dardano A et al (2015) New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 3:638–652CrossRef

Davies MJ, Gross JL, Ono Y et al (2014) Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 16:922–930CrossRef

10.

Derwahl KM, Bailey TS, Wernicke-Panten K et al (2018) Efficacy and safety of Biosimilar SAR342434 insulin Lispro in adults with type 2 diabetes, also using insulin Glargine: SORELLA 2 study. Diabetes Technol Ther 20:49–58CrossRef

11.

Garg S, Dreyer M, Jinnouchi H et al (2016) A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab 18(Suppl 2):25–33CrossRef

12.

Heise T, Hovelmann U, Nosek L et al (2015) Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol 11:1193–1201CrossRef

13.

Heise T, Meneghini LF (2014) Insulin stacking versus therapeutic accumulation: understanding the differences. Endocr Pract 20:75–83CrossRef

14.

Heise T, Nosek L, Bottcher SG et al (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14:944–950CrossRef

15.

Heise T, Pieber TR, Danne T et al (2017) A pooled analysis of clinical pharmacology trials investigating the Pharmacokinetic and Pharmacodynamic characteristics of fast-acting insulin Aspart in adults with type 1 diabetes. Clin Pharmacokinet 56:551–559CrossRef

16.

Home PD, Bergenstal RM, Bolli GB et al (2015) New insulin Glargine 300 units/mL versus Glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 38:2217–2225CrossRef

17.

Hompesch M, Muchmore DB, Morrow L et al (2012) Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther 14:218–224CrossRef

18.

Kapitza C, Nowotny I, Lehmann A et al (2017) Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab 19:622–627CrossRef

19.

Kildegaard J, Buckley ST, Nielsen RH et al (2019) Elucidating the mechanism of absorption of fast-acting insulin Aspart: the role of niacinamide. Pharm Res 36:49CrossRef

20.

Korsatko S, Deller S, Koehler G et al (2013) A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 33:515–521CrossRef

21.

Lane W, Bailey TS, Gerety G et al (2017) Effect of insulin Degludec vs insulin Glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 318:33–44CrossRef

22.

Rege NK, Phillips NFB, Weiss MA (2017) Development of glucose-responsive ‘smart’ insulin systems. Curr Opin Endocrinol Diabetes Obes 24:267–278CrossRef

23.

Riddle MC, Bolli GB, Ziemen M et al (2014) New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 37:2755–2762CrossRef

24.

Rosenstock J, Cheng A, Ritzel R et al (2018) More similarities than differences testing insulin Glargine 300 units/mL versus insulin Degludec 100 units/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care 41:2147–2154CrossRef

25.

Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus(R)) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 17:734–741CrossRef

26.

Schafer-Graf UM, Gembruch U, Kainer F et al (2018) Gestational diabetes mellitus (GDM)—diagnosis, treatment and follow-up. Guideline of the DDG and DGGG (S3 level, AWMF registry number 057/008, february 2018). Geburtshilfe Frauenheilkd 78:1219–1231CrossRef

27.

Tambascia MA, Eliaschewitz FG (2015) Degludec: the new ultra-long insulin analogue. Diabetol Metab Syndr 7:57CrossRef

28.

Yki-Jarvinen H, Bergenstal RM, Bolli GB et al (2015) Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6‑month extension. Diabetes Obes Metab 17:1142–1149CrossRef

Titel: Insulintherapie – neue Insulinanaloga
verfasst von: Dr. med. M. Ehren
Prof. Dr. med. H. H. Klein
Publikationsdatum: 08.08.2019
Verlag: Springer Medizin
Schlagwörter: Typ-1-Diabetes
Typ-2-Diabetes
Hypoglykämie
Insuline
Insuline
Normalinsulin
Insulin Lispro
Insulin Aspartat
Insulin Glargin
Diabetes mellitus
Pharmakokinetik
Erschienen in: Die Innere Medizin / Ausgabe 9/2019
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-019-0652-1

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Neue Technologien in der Diabetestherapie

Diabetestherapie 2.0 – Telemedizin

Outcome-Studien zu SGLT-2-Inhibitoren

Diagnostik und Therapie eines Hereditäres Angioödems

Neuer Behandlungsansatz zur Therapie von Adipositas und Diabetes

44-Jährige mit Brustschmerzen und Schwindel seltener Genese

Praxisempfehlungen der Deutschen Diabetes Gesellschaft